Concord Biotech Ltd

AI

Concord Biotech Ltd

₹ 556 -0.82%
19 Nov - close price
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.

  • Market Cap ₹ 11,642 Cr.
  • Current Price ₹ 556
  • High / Low ₹ 808 / 494
  • Stock P/E 40.9
  • Book Value ₹ 99.2
  • Dividend Yield 0.68 %
  • ROCE 17.1 %
  • ROE 12.9 %
  • Face Value ₹ 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Cons

  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
262 241 319 216 310 244 430 204 247 278 326 257 309
147 135 187 135 176 146 241 143 159 179 208 175 205
Operating Profit 116 106 132 81 134 98 189 61 88 98 118 82 104
OPM % 44% 44% 41% 38% 43% 40% 44% 30% 36% 35% 36% 32% 34%
8 11 11 12 10 17 9 15 16 7 15 14 10
Interest 1 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 13 14 14 13 13 13 15 18 18 19 20 18 18
Profit before tax 110 103 129 80 130 101 184 59 86 86 114 78 95
Tax % 26% 25% 26% 25% 27% 25% 24% 25% 26% 26% 22% 26% 27%
81 78 95 60 96 76 140 44 63 64 88 58 70
EPS in Rs 3.87 3.71 4.54 2.85 4.58 3.63 6.71 2.11 3.04 3.08 4.24 2.80 3.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
239 276 340 436 512 616 713 853 1,017 1,200 1,055 1,170
133 145 212 256 308 289 443 509 585 694 687 768
Operating Profit 105 131 127 180 205 327 270 344 432 506 368 403
OPM % 44% 48% 37% 41% 40% 53% 38% 40% 42% 42% 35% 34%
11 8 36 17 32 14 23 37 37 44 52 46
Interest 1 0 1 1 1 1 6 5 3 1 1 0
Depreciation 10 10 18 19 21 28 50 54 54 54 74 75
Profit before tax 106 129 144 178 214 313 238 322 413 495 345 374
Tax % 34% 33% 30% 33% 21% 25% 26% 25% 25% 25% 25%
70 87 100 118 169 235 175 240 308 372 259 279
EPS in Rs 3.36 4.17 4.80 5.66 8.08 11.25 8.36 11.48 14.73 17.76 12.47 13.50
Dividend Payout % 22% 25% 0% 21% 22% 0% 3% 30% 30% 25% 30%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 7%
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: 1%
3 Years: 1%
TTM: -12%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -4%
1 Year: -23%
Return on Equity
10 Years: %
5 Years: 18%
3 Years: 18%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 9 9 10 10 10 10 10 10 10 10 10 10
Reserves 268 329 585 673 761 990 1,094 1,280 1,516 1,802 2,007 2,065
35 36 22 9 52 86 62 32 10 3 2 2
55 74 69 71 118 97 147 192 164 219 212 249
Total Liabilities 367 448 685 763 941 1,183 1,313 1,514 1,701 2,034 2,232 2,327
104 110 189 230 240 546 573 593 575 795 789 771
CWIP 19 70 3 19 141 18 74 173 211 51 79 112
Investments 42 43 151 229 199 141 74 137 246 335 491 533
202 225 343 285 361 477 592 611 668 854 873 911
Total Assets 367 448 685 763 941 1,183 1,313 1,514 1,701 2,034 2,232 2,327

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
79 155 167 207 246 265 245 267
-42 -114 -195 -112 -158 -155 -160 -143
-37 -43 31 -100 -85 -99 -99 -113
Net Cash Flow 0 -1 3 -4 3 12 -14 11
Free Cash Flow 79 -1 -38 52 101 180 134 172
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 101% 100% 74% 99% 92% 85% 70% 100%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 165 182 236 133 131 105 119 117 125 159 159
Inventory Days 276 321 381 310 312 503 434 430 331 286 485
Days Payable 108 129 210 112 201 152 185 190 150 135 151
Cash Conversion Cycle 334 374 407 331 242 456 368 357 306 310 493
Working Capital Days 195 209 275 177 159 177 161 152 166 193 230
ROCE % 37% 25% 32% 21% 26% 28% 28% 17%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
API Share of Revenue
% of total revenue

Log in to view insights

Please log in to see hidden values.

Login
Capacity Utilization - Unit 1 (API, Dholka)
%
Domestic Share of Revenue
% of total revenue
Top 10 Customer Concentration
% of total revenue
New Customer Additions
count
Capacity Utilization - Unit 3 (API, Limbasi)
%
API Drug Master Files (DMFs) Filed
count (cumulative)

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Nov 2026
44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.09% 44.09%
6.49% 7.11% 8.10% 8.33% 9.35% 9.10% 8.03% 7.58% 7.79% 7.53% 7.28% 7.33%
8.41% 10.35% 9.89% 9.65% 9.16% 8.85% 9.55% 9.58% 9.22% 9.37% 10.95% 11.02%
41.03% 38.46% 37.95% 37.93% 37.41% 37.94% 38.32% 38.75% 38.90% 39.04% 37.68% 37.58%
No. of Shareholders 83,29680,73784,29882,00481,21982,04582,65081,81582,24983,32588,36591,337

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Annual reports

Concalls